| Outcome Measures: |
Primary: Assessment of PK parameter: AUCtau, Sotagliflozin without HCTZ: AUC to the end of the dosing period (AUCtau), Period 1, days 2 to 6|Assessment of PK parameter: AUCtau, Sotagliflozin with HCTZ: AUCtau, Period 2, days 6 to 10 | Secondary: Assessment of PK parameter: AUCtau, HCTZ without sotagliflozin: AUCtau, Period 2, days 4 to 5|Assessment of PK parameter: AUCtau, HCTZ with sotagliflozin: AUCtau, Period 2, days 9 to 10|Assessment of PK parameter: AUCtau, Sotagliflozin-3-O-glucuronide without HCTZ: AUCtau, Period 1, days 2 to 6|Assessment of PK parameter: AUCtau, Sotagliflozin-3-O-glucuronide with HCTZ: AUCtau, Period 2, days 6 to 10|Assessment of PK parameter: Cmax, HCTZ without sotagliflozin: Maximum plasma concentration (Cmax), Period 2, days 4 to 5|Assessment of PK parameter: Cmax, HCTZ with sotagliflozin: Cmax, Period 2, days 9 to 10|Assessment of PK parameter: Cmax, Sotagliflozin-3-O-glucuronide without HCTZ: Cmax, Period 1, days 2 to 6|Assessment of PK parameter: Cmax, Sotagliflozin-3-O-glucuronide with HCTZ: Cmax, Period 2, days 6 to 10|Assessment of PK parameter: tmax, HCTZ without sotagliflozin: Time to reach Cmax (tmax), Period 2, days 4 to 5|Assessment of PK parameter: tmax, HCTZ with sotagliflozin: tmax, Period 2, days 9 to 10|Assessment of PK parameter: tmax, Sotagliflozin-3-O-glucuronide without HCTZ: tmax, Period 1, days 2 to 6|Assessment of PK parameter: tmax, Sotagliflozin-3-O-glucuronide with HCTZ: tmax, Period 2, days 6 to 10|Assessment of PK parameter: Cmax, Sotagliflozin without HCTZ: Cmax, Period 1, days 2 to 6|Assessment of PK parameter: Cmax, Sotagliflozin with HCTZ: Cmax, Period 2, days 6 to 10|Assessment of PK parameter: tmax, Sotagliflozin without HCTZ: tmax, Period 1, days 2 to 6|Assessment of PK parameter: tmax, Sotagliflozin with HCTZ: tmax, Period 2, days 6 to 10
|
